CA2118757C - Aza cyclohexapeptide compounds - Google Patents

Abstract

Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.

Description

TITLE OF THE INVENTION
AZA CYCLOHEXAPEPTIDE COMPOUNDS
The present invention is directed to certain aza cyclohexapeptide compounds and to processes for their preparation.
The aza cyclohexapeptide compounds of the present invention, Compound I (Seq ID Nos. I-IS) are characterized in having a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxy ornithine component (hereinafter "C-5-orn") and may be to represented by the formula R~~N' Rm OH

~ NH-C-RI
N O
R3 O HN CHa HO NH O OOH
O H N
2o R~ N
\ ~~ OH
OH O
HO
wherein R 1 is H or OH
R2 is H, CH3 or OH
R3 is H, CH3, CH2CN, CH2CH~1I-i2 or CH2CONH2 3o RI is C9-C21 alkyl, C9-C21 alkenyl, C1-C10 alkoxyphenyl or C I -C 1 p alkoxynaphthyl RII is H, C1-C4 alkyl, C3-C4 alkenyl, (CH2)2-40H, (CH2)2~NRNRV, CO(CH2) I -4NH2

- 2 - 18955 RIII is H, C1-C4 alkyl, C3-C4 alkenyl, (CH2)2-44H, (CH2)2-4NRIVRV~ or Rn and RIII taken together are -(CH2)4-, -(CH2)5-, s -(CH2)2~(CH2)2- or -(CH2)2-NH-(CHZ)2-RN is H or C 1-C4 alkyl RV is H or C 1-C4 alkyl; and acid addition salts thereof.
Where the expression "alkyl", "alkenyl" or "alkoxy" is employed, it is intended to include branched as well as straight chain radicals.
The compounds of the present invention are generally i s obtained as mixtures of stereoisomeric forms in which one form usually predominates. Conditions may be adjusted by means within the normal skill of the skilled artisan to obtain predominantly the desired isomer.
The compounds with preferred stereoisomeric form designated herein as the "normal" form may be seen in the working examples with the 2o dashed lines below the plane at the "C-5-orn" position. The designation "epi" has been employed for those compounds in which the group at the "C-5-orn" position is above the plane.
Pharmaceutically acceptable salts suitable as acid addition salts are those from acids such as hydrochloric, hydrobromic, 2s Phosphoric, sulfuric, malefic, citric, acetic, tartaric, succinic, oxalic, malic, glutamic and the like, and include other acids related to the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science, 66, 2 (1977).
Representative nuclei for the aza derivatives of the present

3 o invention (Compound I) and the sequence ID for these compounds may be seen in the following table. Since the peptide nuclei would be the same irrespective of substituents RI, R~ or RBI, and since the sequence identification number is assigned for the nuclear variations, the amines and salts have the same sequence B7's.

211 8?57 Aza Compound R 1 R2 ~ R3 SEQ ID
NO
s I-1 H H CH2CONH2 1 I-3 H H ~2~2NH2 3 i o I-6 OH H CH2CH~1I-i2 6 I-9 OH CH3 CH2CH2,NH2 9 is I-11 OH CH3 H 11 I-14 OH OH CH2CH~TH2 14 One of compounds ich is particularly the wh outstanding for the control of nfections mycotic i is a compound identifiable as Compound I-6 wherein Rn i~ H, s 9,11-RBI is CH2CH2NH2 and RI i dimethyltridecyl (DMTD), fically and as which may be referred to speci 2s Compound I-6-1(Seq ID
No.
6).

211 ~7~~

- 4 - 18955 H2N~H
N OH
HO N
H

O
HO NH O
O H N
N
HO OH
O
OH
(161) HO Seq I D No. 6 In the above designation I-6-1 refers to the first compound in which the nuclear arrangement is I-6. Since in all the compounds of the present invention the substituent at the "C-5-orn" is nitrogen, the substituents on said nitrogen may vary and still all compounds which 2 o have the same R l , R2 and R3 would be Seq ID No. 6.
The compounds are soluble in lower alcohols, and polar aprotic solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO) and pyridine. They are insoluble in solvents such as diethyl ether and acetonitrile.
The compounds of the present invention are useful as an antibiotic, especially as an antifungal agent or as an antiprotozoal agent.
As antifungal agents they are useful for the control of both filamentous fungi and yeasts. They are especially adaptable to be employed for the treatment of mycotic infections in mammals, especially those caused by Candida species such as C. albicans, C. tro~icalis and C.
pseudotropicalis, _Crwtococcus species such as C. neoformans and Asperyspecies such as A. fumigatus, A. flavus, A. n, ig-er. They are also useful for the treatment and/or prevention of PneumocXstis carinii 21 ~ 8757

- 5 - 1 A955 pneumonia to which immune-compromised patients are especially susceptible as hereinafter described.
The compounds of the present invention may be prepared from cyclopeptides having the formula OH OH

NH
NH-C-RI
N O
l0 R3 O HN CH3 HO NH O OOH
O H N
Ri N
OH p v OH
HO
(Seq ID Nos. 1-15) by a series of reactions in which the oxygen atom at the "C-5-orn"
(which also may be referred to as the hemiaminal position) is ultimately 2o replaced by nitrogen. The starting materials may be natural products or modified natural products as subsequently described. When R 1 is hydrogen instead of hydroxyl, the product aza compounds may be prepared by an alternate series of reactions. The method applicable for the preparation of compounds in which R 1 may be either H or OH is first described.
The sequence 1Ds of the starting materials are seen in the following table:

- 6 - 18955 Starting Material Compound R I R2 R3 SEQ )D NO.
A-1 H H CH2CONf-I2 16 i o A-6 OH H CH2CH~1I-i2 2 I

i s A- I 1 OH ~3 H 26 A-14 OH OH CH2~2~2 29 Compounds A-4 and A-7 have been identified in the literature (J. Antibiotics 45, 1855-60 Dec. 1992) as pneumocandin Bo and pneumocandin Ao when R1= DMTD.
When in Compound A-1, R I and R2 are represented by any 25 of the possible variables and R3 is -H, CH3 or -CH2CONH2 (Seq 1D
Nos. 16, 19, 22, 25-27 and 30), they may be directly employed in the first method. When R3 is -CH2CN or -CH2CH2NH2, the group -CH2CONH2 may be first converted to -CH2CN or -CH2CH2NH2 as subsequently disclosed and all the modified compounds (Seq B7 Nos.
3 0 17_ I 8, 20-21, 23-24, 28-29) used in the first method, or alternatively, a compound in which R3 is -CH2CONH2 may be employed to produce a compound with N at the hemiaminal position, and the -CH2CONH2 of the resulting product then converted to -CH2CN or -CH2CH2NH2.

- '1 - 18955 First, when R 1, R2 and R3 of the starting material are the same as that in the product, the following sequence may be employed.

O * O
NH
NH-C-RI
N O
Rs O HN CH H2NCH2CH2SH

1o HO NH O OH H+
O H
Ri N N Step A
OH O OH
HO
(A) (Seq ID Nos 16-30) 2.2 [o]
O
~~-NH Step B
(B) (Seq I D Nos 31-45) * The position is the "C-5-orn" or the hemiaminal position.

O\\
H_2,Pd/C ~~NH
N OH S P (I) s 3 p (Seq ID Nos 1-15) -~-- N H >
(D) LiN3 (Seq ID Nos 1-15) Stpn (~

O
-- N H
'~"r (C) \
(Seq ID Nos 31-45) R~I~~H
normal Step C' or epi Rii 2o R~~~ --N OH
O
--NH
normal or epi 2s (I) (Seq ID Nos 1-15) In Step A, the starting material Compound A (Seq m Nos.
16-30), alkylthiol or arylthiol and acid are caused to react in an aprotic 3 o solvent under anhydrous conditions for time sufficient for reaction to take place with the formation of Compound B (Seq ID Nos. 31-45), seen in the following table. Aminoethylthiol has been found to be useful for this step.

211 s~57 Sulfur Intermediate Compound R1 R2 R3 SEQ m B-3 H H ~2~2NH2 33 1 o B-6 OH H ~2~2~2 36 i s g_ I 1 OH ~3 H 41 B- I 4 OH OH CH2CH~NH2 44 For Step A, suitable acids include strong organic acid and mineral acids. Examples of strong organic acids are camphorsulfonic acid, p-toluenesulfonic acid and methanesulfonic acid. Mineral acids include hydrochloric acid and hydrobromic acid. Camphorsulfonic acid 2s is preferred.
Suitable solvents include DMF, DMSO, 1-methyl-2-pyrrolidinone and hexamethyl phosphoric triamide (HMPA). DMF or DMSO is preferred.
The reaction is generally carried out at ambient 3 o temperature for from 1 to about 10 days.
In carrying out the reaction, the cyclohexapeptide compound, the thiol compound and acid are stirred together in a suitable solvent until the reaction is substantially complete. The reaction mixture then is diluted with water and flash chromatographed on reverse phase resins using 10 to 40 percent acetonitrile/water (containing O.lo trifluoroacetic acid) as eluant. Trifluoroacetic acid may hereinafter be designated "TFA". The fractions containing the desired product may be concentrated and lyophilized and the lyophilized material purified by preparative high performance liquid chromatography (HPLC).
Appropriate columns for HPLC are commercially available columns sold under trade marks such as "ZORBAX"
(DuPont), "DeltaPak" (Waters), Bio-Rad (Bio-Rad), "LICHROPREP" RP18 (E. Merck). The specific columns are identified in the working examples.
In Step B, Compound C (Seq ID Nos. 31-45), a sulfone is obtained by the oxidation of Compound B. Suitable oxidizing agents or oxidants include "OXONE" (Trade-mark) (KHSOS~KHS04~K2S04 2:1:1, Aldrich Chemicals) metachloroperoxybenzoic acid, and peroxyacetic acid. The sequence ID of Compound C is the same as that of Compound B since the atom attached to the hemiaminal carbon is still sulfur. Thus, the sequence IDs of the sulfones are as follows:

21~s757 Sulfone Compound R 1 R2 R3 SEQ ID

s C-2 H H CH2CN 32 i o C_7 OH CH3 CH2CONH2 37 C-9 OH CH3 ~2~2~2 39 i s C-12 OH OH CH2CONH2 42 C-14 OH OH CH2CH~TH2 44 20 The oxidation of the thioether (Compound B) to the sulfone (Compound C) is carried out with about two molar amounts of the oxidant. When one molar amount of oxidant is employed, the product is a sulfoxide which may then be converted to the sulfone. The sulfoxides may be employed as an intermediate in the formation the aza 2 s compounds but the sulfone is preferred. A slight excess over the two molar amount of the oxidizing agent is employed.
The reaction is carried out in an aqueous medium, preferably a mixture of acetonitrile and water. About equal amounts are preferred although a range of 1:9 to 9:1 may be employed.
3 o In carrying out the reaction, the oxidant is added to a solution of Compound B (Seq ID Nos. 31-45) in 1:1 acetonitrile/water and the mixture allowed to stand at ambient temperature for time sufficient to complete the reaction to obtain Compound C generally from about 30 minutes to one hour.

21~e757 a After completion of the reaction, the compound is recovered from the reaction mixture by diluting with water and chromatographing. Reverse phase (C18) flash column chromatography is suitable in this purification step. The preferred eluting agent is 30-45 percent acetonitrile/water (0.1 % TFA) in 5 percent step gradients. The appropriate fractions are lyophilized to recover the desired sulfone intermediate, Compound C (Seq ID Nos. 31-45). The intermediate tends to be labile, thus the isolation should be carried out as rapidly as possible.
1 o Compound C may be converted to a compound having a nitrogen directly attached to the "C-5-orn". As seen in the flow diagram, reaction of Compound C with an alkali metal azide produces an azide at that position (Compound D) while reaction with an amine compound (ammonia or amine) produces an amino group at the "C-5-1 s orn" position, (Compound I). Compound D is an important intermediate for most of the compounds of the present invention.
Although Compound D has nitrogen at "C-5-orn", since it is not a product, separate sequence ID Nos. are assigned for Compound D.
Sequence 117 Nos. for Compound D are found in the following table.

Azide Compound R I R2 R3 SEQ ID

s D-2 H H CH2CN 47 D-3 H H ~2~?~2 4R

D-6 OH H ~2~2~2 51 1 o D_7 OH CH3 CH2CONH2 52 D-9 OH CH3 CH2CH~,NH2 54 i s D- I 2 OH OH CH2CONH2 57 20 The azide may be obtained by adding alkali metal azide while stirring at ambient temperature to a solution of the sulfone (Compound C; Seq. ID Nos. 31-45) in an aprotic solvent for time sufficient to complete the reaction with the formation of the azide as determined by HPLC analysis. The reaction mixture then may be 2s diluted with aqueous acid such as trifluoroacetic acid and then chromatographed to separate the desired azide (Compound D) from the reaction mixture. Reverse-phase (C 18) flash column chromatography using I 0-25 percent acetonitrile/water (0.1 % TFA) in 5 percent step gradients is suitable for this procedure.
3 o The azide (Compound D) may then be reduced to a compound having a free amino group which is among the products (Compound I, Seq ID Nos. 1-IS) of the present invention.
The reduction may be carried out by mixing the azide compound (Compound I) with Pd/C in a solvent such as glacial acetic acid and hydrogenating under balloon pressure for 10 to 20 hours. The product then may be recovered by first removing the catalyst by filtration and the filtrate lyophilized to obtain the amine compound (Seq ID 1-15) in which the amine is a primary amine.
The amine thus obtained may be converted into a substituted amine as subsequently described.
Compound I in which -NRBRIII is represented by -NHCH2CH2NH2 or generically by -NH(CH2)2~NR~RV may be prepared from the sulfone by a method in which a diamine H~1(CH2)2-l0 4NRIVRV is caused to react with the sulfone (Compound C, Seq m Nos. 31-45).
The reaction is carried out in an aprotic solvent such as those previously named and at ambient temperature. About tenfold molar excess of the amine compound is employed. The reaction may be i5 carried out over one to several hours.
In carrying out the reaction, the appropriate amine is added to a solution of the sulfone in anhydrous aprotic solvent and the reaction mixture stirred at ambient temperature to obtain Compound I (Seq ID
Nos. 1-15) in which the substituent at "C-5-orn" is -NRIIRIB. The 2o desired compound may then be recovered by diluting with aqueous trifluoroacetic acid and then chromatographing. Reverse phase (Cl R) flash column chromatography eluting with 10 to 25% acetonitrile/water (0.1 % TFA) in 5 percent step gradients is suitable. The appropriate fractions may be lyophilized to recover the product as a trifluoroacetate Salt.
The trifluoroacetate salt may be converted by dissolving the salt in water and passing through a Bio-Rad AG2-X8(Cl-) polyprep column and recovering the product as the hydrochloride salt.
When R 1 in formula (I) is hydrogen, Compound I' (Seq ID
3o Nos. 1-3, 15), the nitrogen may be introduced directly into the hemiaminal position by a reaction to form the azide, which then is reduced to an amine which optionally may be alkylated or acylated to obtain the ultimate product. The reaction is seen by the following flow diagram.

21~8~57~

O
NH
NH-C-R~ Ns OH
N NaN3 O
O -~ ~- N H
Rs O HN CH3 TFA
HO NH O \OH
H O H N
N
to I \ OH O OH
HO
(A') H2, 10% Pd-C H2N OH

~~ N H
Although R 1 is hydrogen in some natural product 2o cyclohexapeptides, RI is more commonly hydroxyl. Thus, for a number of the compounds, Compound A' in the flow diagram is prepared as a first step from the corresponding compound in which R I
is OH.
The preparation of the reduced compound may be carried 2s out by stirring the appropriate hydroxy compound in LiC104-diethyl ether at room temperature, adding trifluoroacetic acid, followed by triethylsilane and subjecting the mixture to rapid stirring for from 4 to hours or until the starting hydroxy compound is no longer detectable by analytical HPLC. The reaction mixture is then poured into distilled 3 o water to obtain the reduced product as precipitate which then is recovered by conventional procedures. The reduced product thus obtained may be used with or without purification in the preparation of the azide.
Products in which R I is H, may be obtained by adding the modified cyclohexapeptide to a preformed solution of HN3. HN3 may be prepared from sodium azide and trifluoroacetic acid. The reaction is allowed to take place at room temperature to obtain the azide product which may be recovered by conventional procedures and purified by HPLC.
The purified azide compound may be reduced to the amine compound by hydrogenating with palladium/carbon in a manner similar to that previously described.
The amines, prepared as above and having a primary amino group -NH2 described, may then be alkylated by conventional means to obtain a substituted amino group. Briefly, alkylation may be carried out by causing an appropriately substituted alkyl halide to react with the amine (Compound I, NRBRIII=NH2; Sequence ID Nos 1-15) in an aprotic solvent in the presence of a base to obtain the monosubstituted amine (Compound I, NRIIRIII=NHRII wherein R~ is C1-C4 alkyl, C3-i5 C4 alkenyl, (CH2)2-40H, and (CH2)2-4NRIVRV). The latter may be recovered from the reaction mixture by conventional procedures.
The amines, prepared as above described and having a primary amino group -NH2, may be acylated by conventional means to obtain an acylated amino group. The acyl group contemplated is 2 o CO(CH2) 1-4NH2. Since this is a primary amino group, the amino of the acylating acid is protected such as with a benzyloxycarbonyl group before the acylation is carried out. An activated ester such as the pentafluorophenyl ester is preferably used. The acylation may be carried out in an aprotic solvent in the presence of base such as diisopropylethylamine at ambient temperature for from one to several hours to obtain the acylation product. The product may be recovered by diluting the reaction mixture with methanol and purifying by HPLC.
The protecting group may be removed by conventional hydrogenolysis.
(Compound I, -NRUR~=-NHCO(CHZ) 1-4NH2).
The amine compounds in which the amino group at the hemiaminal position is totally substituted, i.e. when neither RB nor RBI
is 21~875~

II
R NR~I OH
O
-NH
hydrogen, are preferably prepared by reacting the sulfone (Compound B Seq ID No. 31-45) with an appropriately substituted amine RIIRII1NH. The reaction may be carried out by adding the amine to a stirred solution of the sulfone for time sufficient for reaction to take 1 o place. The product may be recovered by purifying by preparative HPLC and lyophilizing the appropriate components.
The invention also embraces acid addition salts. The compound in the normal course of isolation is obtained as an acid addition salt. Generally, it is as a trifluoroacetic acid salt. The salt thus obtained may be dissolved in water and passed through an anion exchange column bearing the desired anion. The eluate containing the desired salt may be concentrated to recover the salt as a solid product.
The compounds of the present invention are active against many fungi and particularly against Candida species. The antifungal 2o properties may be illustrated with the minimum fungicidal concentration (MFC) determination against certain andida organisms in a microbroth dilution assay carried out in a Yeast Nitrogen Base (DIFCO) medium with 1 % dextrose (YNBD).
In a representative assay, compounds were solubilized in 100% dimethyl sulfoxide (DMSO) at an initial concentration of 5 mg/ml. Once dissolved, the drug stock was brought to a concentration of 512 ~g/ml by dilution in water such that the final DMSO
concentration was about 10 percent. The solution was then dispensed via a multichannel pipetter into the first column of a 96-well plate (each 3o well containing 0.075 ml of YNBD), resulting in a drug concentration of 256 ~g/ml. Compounds in the first column were diluted 2-fold across the rows yielding final drug concentration ranging from 256 ~g/ml to 0.12 ~g/ml.
Four-hour broth cultures of organisms to be tested were adjusted using a spectrophotometer at 600 nm to equal a 0.5 McFarland Standard. This suspension was diluted 1:100 in YNBD to yield a cell concentration of 1-5 x 104 colony forming units (CFU)/ml. Aliquots of the suspension (0.075 ml) were inoculated into each well of the microtiter plate resulting in a final cell inoculum of 5-25 x 103.
CFU/ml and final drug concentrations ranging from 128 ~g/ml to 0.06 ~g/ml. Each assay includes one row for drug-free control wells and one row for cell-free control wells.
After 24 hours of incubation, the microtiter plates were shaken gently on a shaker to resuspend the cells. The MIC-2000 1 o inoculator was used to transfer a 1.5 microliter sample from each well of the 96-well microtiter plate to a single reservoir inoculum plate containing Sabouraud dextrose agar (SDA). The inoculated SDA plates were incubated for 24 hours at 35°C. The results were as follows:

--~- ~E .ice W N .-.

v.r 'r .r w.r x x x ' a d x x x x a~ ~ ~ N

a: "'~ n n n O
O

D. N N N N 7G
x x o x z z x z N

N N N

x x x x x x x z z x N
N N

0 ~ .r O

O N N O
O

n O
o O O o .,. ~ ~, ;r r N
~~ O t,Nn 00 v~

O O ~-. O
O~ N ~ i.r J
O ~~

O

O
O ~ C
c ~ ~ c. C ~' Nr~ r.

'" o r .

n 0 0 o p O N "C O
O O O

r O c~

H.r N r r.

The compounds also show in vivo effectiveness against fungi which may be demonstrated with the same compounds of the in vitro assay.
Growth from an overnight SDA culture of andida albicans MY 1055 was suspended in sterile saline and the cell concentration determined by hemacytometer count and the cell suspension adjusted to 3.75 x 105 cells/ml. Then 0.2 milliliter of this suspension was administered I.V. in the tail vein of mice so that the final inoculum was 7.5 x 104 cells/mouse.
1 o The assay then was carried out by administering aqueous solutions of Compound I at various concentrations intraperitoneally (LP.), twice daily (b.i.d.) for four consecutive days to 18 to 20 gram female DBA/2 mice, which previously had been infected with Candida albicans in the manner described above. Distilled water was 1 s administered LP. to C. albicans challenged mice as controls. After seven days, the mice were sacrificed by carbon dioxide gas, paired kidneys were removed aseptically and placed in sterile polyethylene bags containing 5 milliliters of sterile saline. The kidneys were homogenized in the bags, serially diluted in sterile saline and aliquots 2o spread on the surface of SDA plates. The plates were incubated at 35°C
for 48 hours and yeast colonies were enumerated for determination of colony forming units (CFU) per gram of kidneys. Compounds (1), (2), (3) and (4) gave >99 percent reduction of recoverable C ndi a CFUs at 0.09 and 0.375 mg/kg LP. twice daily for four consecutive days.
2s The compounds of the present invention are also useful for inhibiting or alleviating Pneumocystis carini infections in immune-compromised patients. The efficacy of the compounds of the present invention for therapeutic or anti-infection purposes may be demonstrated in studies on immunosuppressed rats.
3 o In a representative study, the effectiveness of Compound I-6-1 (R1 = OH; R2 =H; R3 = CH2CH2NH2; RI = DMTD; RII = H; RBI
= CH2CH~TH2) was determined. Sprague-Dawley rats (weighing approximately 250 grams) were immunosuppressed with dexasone in the drinking water (2.0 mg/L) and maintained on a low protein diet for 2118a~~

seven weeks to induce the development of pneumocystis pneumonia from a latent infection. Before drug treatment, two rats were sacrificed to confirm the presence of PneumocYStlS carinii pneumonia (PCP); both rats were found to have infections. Five rats (weighing approximately 150 grams) were injected twice daily for four days subcutaneously (sc) with Compound I-6-1 in 0.25 ml of vehicle (distilled water). A vehicle control was also carried out. All animals continued to receive dexasone in the drinking water and low protein diet during the treatment period.
At the completion of the treatment, all animals were sacrificed, the l o lungs were removed and processed, and the extent of disease determined by microscopic analysis of stained slides. The results of this study showed Compound I-6-1 reduced P. carinii cysts in 5 rats by at least 90 percent when dosed at .075 mg/kg with all rats surviving.
The outstanding properties are most effectively utilized 1 s when the compound is formulated into novel pharmaceutical compositions with a pharmaceutically acceptable carrier according to the conventional pharmaceutical compounding techniques.
The novel compositions contain at least a therapeutic antifungal or antipneumocystis amount of the active compound.
2o C,enerally, the composition contains at least 1% by weight of Compound I. Concentrate compositions suitable for dilutions prior to use may contain 90% or more by weight. The compositions include compositions suitable for oral, topical, parenteral (including intraperitoneal, subcutaneous, intramuscular, and intravenous), nasal, 2 s ~d suppository administration, or insufation. The compositions may be prepacked by intimately mixing Compound I with the components suitable for the medium desired.
Compositions formulated for oral administration may be a liquid composition or a solid composition. For liquid preparation, the 3 o therapeutic agent may be formulated with liquid carriers such as water, glycols, oils, alcohols, and the like, and for solid preparations such as capsules and tablets, with solid carriers such as starches, sugars, kaolin, ethyl cellulose, calcium and sodium carbonate, calcium phosphate, kaolin, talc, lactose, generally with lubricant such as calcium stearate, together with binders disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage form. It is especially advantageous to formulate the compositions in unit dosage form (as hereinafter defined) s for ease of administraion and uniformity of dosage. Compositions in unit dosage form constitute an aspect of the present invention.
Compositions may be formulated for injection and may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles such as 0.85 percent sodium chloride or 5 percent i o dextrose in water and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Buffering agents as well as additives such as saline or glucose may be added to make the solutions isotonic. The compound may also be solubilized in alcohol/propylene glycol or polyethylene glycol for drip intravenous 1 s administration. These compositions also may be presented in unit dosage form in ampoules or in multidose containers, preferable with added preservative. Alternatively, the active ingredients may be in powder form for reconstituting with a suitable vehicle prior to administration.
20 ~e term "unit dosage form" as used in the specification and claims refers to physically discrete units, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the pharmaceutical carrier.
Examples of such unit dasage forms are tablets, capsules, pills, powder 2s packets, wafers, measured units in ampoules or in multidose containers and the like. A unit dosage of the present invention will generally contain from 100 to 200 milligrams of one of the compounds.
When the compound is for antifungal use any method of administration may be employed. For treating mycotic infections, oral 30 or intravenous administration is usually employed.
When the compound is to be employed for control of pneumocystis infections it is desirable to directly treat lung and bronchi.
For this reason inhalation methods are preferred. For administration by inhalation, the compounds of the present inventions are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of Compound I in suitable propellants, such as fluorocarbons or hydrocarbons.
Although the compounds of the present invention may be employed as tablets, capsules, topical compositions, insufflation powders, suppositories and the like, the solubility of the compounds of the present invention in water and aqueous media render them adaptable to for use in injectible formulations and also in liquid compositions suitable for aerosol sprays.
The following examples illustrate the invention but are not to be construed as limiting.
Examples I -3 illustrate the preparation of the products by 15 the first method described, namely proceeding through the sulfone.
This method may be employed in the preparation of any of the compounds but must be employed to obtain a useful yield of product when R 1 is OH.
Examples 4 and following illustrate preparation of the 2o products by direct substitution of nitrogen for oxygen into the hemi-aminal position "5-orn". This method is preferred when R 1 is H, and RII and RIII are H.
Example 3 illustrates employing as starting material, a compound in which R3 has already been reduced to CH2CH~TH2 from 2s ~ ~e natural product state where R3 is CH2CONH2. Similarly for compounds in which R3 is -CH2CN, the already partially modified compound may be employed.
Examples 9 and 10 illustrate carrying out the conversion of the hemiaminal oxygen to nitrogen and then converting the CH2CN or 3 0 ~2CH~2.

2118'57 r H2N~ H
N ,OH
HO O
N
..,. H H
l0 O N
O
.,..H
H2 HO' NH O
O H H; N
H O; ~,, N
H O OH Seq. ID. No. 4 OH
HO
Part A. Preparation of Intermediate I-(4-hydroxy-5-(epi)-aminoethylthio-N2-( 10,12-dimethyl-1-oxotetradecyl)ornithine]-5-(3-hydroxyglutamine)-6-(3-hydroxXproline)echinocandin B (Seq ID No 34) A solution of 500 mg (0.47 mmol) of pneumocandin Bo (Seq ID No 19), 5.34g (47 mmol) of 2-amino-ethanethiol hydrochloride and 109 mg (0.47 mmol) of (1S)-(+)-10-camphorsulfonic acid in 40 ml anhydrous DMF was stirred at 25°C for 6 days. The reaction mixture was diluted with 40 ml of water and flash chromatographed on '~LICHROPREP" RP18 (40-63 Vim, lS.Og) packed with 10%
acetonitrile/water. The column was eluted with 10 to 40%
acetronitrile/water, collecting two 120 ml fractions at each 10 percent gradient. From the two 40% acetonitrile/water fractions was obtained 185 mg of material which was purified by preparative HPLC
"ZORBAX" C8 (21.2 x 250mm), eluting with 40-45%

acetonitrile/water (0.1 % TFA) to obtain 128 mg of 1-[4-hydroxy-5-(epi)-aminoethylthio-N2-( 10,12-dimethyl-1-oxotetradecyl)-ornithine]-5-(3-hydroxyglutamine)-6-(3-hydroxyproline)-echinocandin B
trifluoroacetate as a white amorphous solid.
s 1 H NMR (400 MHz, CD30D) 8 1.34 (d, J= 6.3 Hz, 3H), 2.89 (m, 2H), 4.72 (d, J=4.9 Hz, 1 H) FAB-MS (Li), mle 1131 (MH+Li)+
Part B. Preparation of Intermediate Sulfone (Sect. ID 34) to To a stirred solution of the thio compound (444 mg, 0.358 mmol) obtained in Part A, in 15 mL of 1:1 acetonitrile/water was added "OXONE" (324 mg equivalent to 1.06 mmol of potassium hydrogen persulfate). After about 45 minutes, the solution was diluted with an equal volume of water and rapidly chromatographed using reverse-is phase (C18) flash chromatography column eluting with 35-43%
acetonitrile/water (0.1 % TFA) in 2% step gradients. The product containing fractions were lyophilized to obtain 357 mg (86% yield) of the epi-sulfone.
1 H NMR (400MHz, CD30D) ~ 3.48 (m, 2H), 3.55 (m, 1 H), 3.71 20 (m~ 1 H), 3.91 (dd, 1 H), 4.00 (m, 1 H), 5.17 (dd, 1 H), 6.76 (d, 2H),

7.16 (d, 2H) Part C. Preparation of Product of Formula ( 1 ); Compound I-4 (Seq ID No 4) 2 s To a stirred solution of 1.2 g (0.945 mmol) of epi-sulfone (prepared as described in Part B) in 20 mL of anhydrous DMF was added ethylenediamine (568 mg, 9.45 mmol). After 1 hour, HPLC
analysis (RP-C18, 40% CH3CN/H20 (0.1 % TFA)) of the reaction mixture indicated complete conversion to two polar products in a ratio 30 of 37:63. Reverse phase (C18) flash column chromatography eluting with 10-40% acetonitrile/water (0.1 % TFA) in 5 percent step gradients was followed by lyophilization of the appropriate fractions to provide 200 mg (21 % yield) of the normal product as the (bis)-trifluoroacetate salt.

1H NMR (400 MHz, CD30D) 8 1.14 (d, J=6.2 Hz, 3H), 2.72 (dd, J=15.4 and 3.8 Hz, 1 H), 4.10 (m, H), 5.04 (dd, J=8.7 and 3.2 Hz, 1H), 5.09 (dd, J=8.5 and 4.2 Hz, 1H), 5.18 (br s, 1H), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.47 (d, J=8.6 Hz, 1H), 7.71 (d, J=10.0 Hz, 1H),

8.11 (d, J=8.7 Hz, 1H), 8.71 (d, J=8.7 Hz, 1H).
FAB-MS (Li), m/z 1113.5 (MLi)+.
The (bis)-trifluoroacetate salt from above was dissolved in H20 and the solution passed through a Bio-Rad AG2-X8 (C1-) polyprep column washing with additional water. The product-containing eluate was lyophilized to give the above compounds as the (bis)-hydrochloride salt.
(Bio-Rad is a Trade-mark.) Lyophilization of the fractions containing the major product provided epi-product 1H NMR (400 MHz, CD30D) 8 3 . 02 (m, 1H) , 3 . 14 (m, 3H) , 4.16 (m, 1H), 5.10 (dd, 1H), 6.76 (d, 2H), 7.14 (d, 2H).
FAB-MS (Li), m/z 1113.9 (MLi)+.

3 HCI . NH OH
HO O
N
.,. H H

O
w~~ H ~~
HO' NH O
O H H~, N
N (2) HO; ~,,H O '~'OH Seq. ID No. 6 OH
HO
Part A. Preparation of Intermediate Sulfone (Seq. ID No. 36) 2o The starting compound, Compound A-6 RI = DMTD (Seq.
ID No. 21 ), was prepared as described for such compound in the section entitled Preparation of Starting Materials.
Compound A-6 was then converted to the epi-thio compound Compound B-6 (Seq ID. No. 36) in a manner similar to that 2s described in Part A of Example 1.
To a stirred solution of 285 mg (0.241 mmol) of Compound B-6 in 14 mL of 1:1 acentonitrile/water was added "OXONE" (162 mg equivalent to 0.530 mmol of potassium hydrogen persulfate). After a period of 45 minutes, the solution was diluted with 3 o an equal volume of water and chromatographed. Reverse-phase (C 18) flash column chromatography eluting with 30-45% acetonitrile/water (0.1 % trifluoroacetic acid) in 5% step gradients was followed by lyophilization of the product-containing fractions to provide 212 mg of the epi-sulfone (Compound C-6 Seq ID. No. 36) Yield = 84%.

1 H NMR (400 MHz, CD30D) 8 3.08 (M, 2H), 3.46 (t, J=6.6 Hz, 2H), 3.68 (m), 5.05 (M), 6.77 (d, J= 8.5 Hz, 2H), 7.15 (d, J=8.5 Hz, 2H) FAB-MS (Li), m/z 1039.9 Pan B. Preparation of the Product of Formula (2) (Compound I-6: RB=H: RIB=2-aminoeth~l); Sect 117 No. 6 To a stirred solution of Compound C-6 (prepared as described in Pan A, 418 mg, 0.305 mmol) in 10 mL of anhydrous N,N-dimethylformamide was added ethylenediamine ( 183 mg, 3.05 1 o mmol). After a period of 1 h, HPLC analysis (RP-C 18, 35 %
CH3CN/H20 (0.1 % CF3COOH)) of the reaction mixture indicated complete conversion to two polar products in a ratio of 36:64. The reaction mixture was diluted with aqueous trifluoroacetic acid ( 190 mL
H20, 0.4 mL CF3COOH) and chromatographed. Reverse-phase (C18) flash column chromatography eluting with 10-25% acetonitrile/water (0.1 % trifluoroacetic acid) in 5% step gradients was followed by lyophilization of the appropriate fractions to provide 111 mg of the product as the (tris)-trifluoroacetate salt:
field=25%
1 H NMR (400 MHz, CD30D) 8 1.17 (d, J=6.2 Hz), 2.44 (dd, J=7.0 and 13.2 Hz, 1H), 2.7-3.0 (m, 4H), 3.06 (t, J=7.0 Hz, 2H), 3.82 (m, 3H), 3.97 (dd, J=11.2 and 3.2 Hz, 1 H), 4.03 (m, 2H), 4.70 (d, J=2.3 Hz, 1 H), 5.00 (d, J=3.3 Hz, 1 H), 6.75 Hz (d, J=R.6 Hz, 2H), 7.11 (d, J=8.6 Hz, 2 s 2~
FAB-MS (Li), m/z 1099.9 (MLi)+, 1033.9 The (tris)-trifluoroacetate salt from above was dissolved in H20 and the solution passed through a Bio-Rad AG2-X8 (Cl-) polyprep column washing with additional water. The product-containing eluate 3 o was lyophilized to give 93 mg of the above compound as the (tris)-hydrochloride.

21~s~~7 HCI
H2N ,OH
HO O
N
.,,. H H
O N
1o O
H2N ~~~~H
HO NH O
O H H, N
N
HO '~,H .~'OH 3 O
1 s OH Seq. i D No. 4 HO
Part A: Preparation of Azide (Sect. ID No. 49) 2o To a stirred solution of 297 mg, 0.257 mmol epi-sulfone (Example 1, Part B) in 10 milliliters of anhydrous dimethylformamide was added lithium azide ( 126 mg, 257 mmol). After a period of 1 hr, HPLC analysis (RP-18, 40% CH3CN/H20 (0.1 % of CF3COOH)) of the reaction mixture indicated complete conversion to a single substantially 2s ~ less polar product. Reverse phase (C18) flash column chromatography eluting with 30-65% acetonitrile/water in 5% step gradients was followed by lyophilization of the product-containing fractions to provide crude azide. Preparative HPLC (C18, 40-45% CH3CN /H20 (0.1 % CF3COOH) in one 5% step gradient) produced an azido s o compound, Compound D-4, (Seq. ID No. 49).
1 H NMR (400 MHz, CD30D) S 1.14 (d, J=6.1 Hz, 3H), 2.50 (dd, J=15.6 and 9.9 Hz, 1 H), 2.84 (dd, J=15.6 and 3.3 Hz, 1 H), 3.95 (dd, J=11.2 and 3.1 Hz, 1H), 4.05 (m, 2H), 4.56 (m, 3H), 4.98 (dd, J=8.5 and 3.5 Hz, 1 H), 5.10 (dd, J=8.3 and 4.2 Hz, 1 H), 5.26 (dd, J=8.5 and 2.2 Hz, 1H), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.44 (d, J=8.3 Hz, 1 H), 7.76 (d, J=9.9 Hz, 1 H), 8.26 (d, J=8. I Hz, 1 H), 8.83 (d, J=8.7 Hz, 1 H), 9.00 (d, J=8.5 Hz, 1 H) FAB-MS (Li), m/z 1096.9 (MH+Li)+
IR (Nujol mull, cm-1) 2110 s Part B: Preparation of the Amine (Sea. ID No. 4) A mixture of azido compound D-4, prepared in Part A, ( 137 mg, 0.126 mmol) and 10% Pd/C ( I 37 mg) in glacial acetic acid ( I 0 mL) was hydrogenated under balloon pressure for a period of 14 h.
to The catalyst was removed by filtration and the filtrate was lyophilized to obtain the crude amine. Purfication by preparative HPLC (C I 8, 35-41 % CH3CN/H20 (0.1 % CF3COOH) in 3% step gradients), followed by lyophilization of the appropriate fractions provided the aza compound, Compound I-1, RB, RIII = H (Seq. ID No. I) as the is trifluoroacetate salt: Yield = 48%
1 H NMR (400 MHz, CD30D) ~ 1.13 (d, J=6.1 Hz, 3H), 2.49 (dd, J=15.6 and 9.8 Hz, I H), 2.81 (dd, J=15.6 and 3.4 Hz, 1 H), 3.97 (dd, J=11.1 and 3.1 Hz, 1H), 4.03 (m, lH), 4.11 (m, IH), 4.47 (dd, J=11.7 and S.5 Hz, 1 H), 4.57 (m, 2H), 5.00 (m, 1 H), 5.10 (m, I H), 5.14 (d, 2o J=2.2 Hz, IH), 6.74 (d, J=8.6 Hz, 2H), 7.12 (d, J=8.6 Hz, 2H), 7.42 (d, J=8.3 Hz, 1 H), 8.89 (d, J=8.8 Hz, 1 H) FAB-MS(Li), m/z 1071.0 (MLi)+
The trifluoroacetate was dissolved in H20 and the solution passed through a Bio-Rad AG2-X8 (Cl-) polyprep column, washing 2 s ~,~,i~ additional water. The product-containing eluate was lyophilized to obtain 66 mg of compound I-4, RB, RIU = H (Seq ID No. 1 ) as the hydrochloride.

21~s757 In the following experiments, Solvent A = 95% water/5%
acetonitrile/0.1 % trifluoroacetic acid and Solvent B = 95 %
acetonitrile/5% water/0.1 % trifluoroacetic acid. When the expression ' "in vac " or "rotovaped" is used, it refers to removal of solvent on a rotary evaporator.

~HOAc H2N OH
O
HO
.,~ H H
O N
O
H2N ~--~" H
HO NH
O H H, N
N
'~, 'r H O OH geq. ID No. 1 OH
HO
A. Preparation of Intermediate Azide Compound D-1 (Seq ID
2s No 46) Pneumocandin Bp (Compound A-4; Seq ID No. 19) (5.00 g, 4.69 mmol) was dissolved in 2M LiC104 - diethyl ether at room temperature. Trifluoroacetic acid (2.50 ml) was added to the stirring solution followed by triethylsilane (5.00 ml). The heterogeneous 3 o mixture was stirred rapidly for 6 hours after which time little or no starting pneumocandin Bp was detectable by analytical HPLC (C 18 "ZORBAX", 45% Solvent A/55% Solvent B/0.1% TFA, 1.5 ml/min).
The mixture was poured into 200 ml of distilled water, filtered and air dried. The wet solid was stirred with diethyl ether, filtered and air dried to obtain 5.6 g of crude monoreduced pneumocandin Bo. (Compound A-l; Seq ID No. 16).
The crude isolate from above was added, as a solid, to a preformed solution of HN3 prepared by dissolving NaN3 (3.06 g, 47.0 mmol) in 100 ml of trifluoroacetic acid with cooling. After stirring at room temperature for 30 minutes, the reaction mixture was poured into 350 ml of distilled water and stirred for 15 minutes. The precipitate was filtered, dissolved in methanol and the solvent removed in vacuo. The residual water was removed by azeotropic removal with 100%
ethanol. The final solid was subjected to high vacuum to remove volatiles. The mixture was purified in two equal batches by preparative HPLC (C18 "DELTAPAK", 60 ml/min, 48 ml fractions) using a step gradient elution from 70%
A/30% B to 50% A/50% B. The appropriate fractions were combined (determined by W monitoring at ~=220 and 277 nm). Impure fractions were combined and reprocessed in a similar fashion as described above. A total of 1.78 g (35% yield) of azide D-1 (Seq ID No. 46) was obtained in this manner. 1H NMR (400 MHz, CD30D): 8 7.02 (d, 2H), 6.69 (d, 2H), 5.30 (d, 1H), 5.11 (d, 1H), 4.98 (d, 1H), 2.74 (dd, 1H), 1.13 (d, 3H). FAB-MS (Li), m/z 1081 (MH+Li)+.
(DELTAPAK is a Trade-mark.) - 32a -B. Preparation of Amine of Formula (4) Compound I-1 (RII, RIII - H (Seq ID No.l) The purified azide compound D-1 prepared above (1.50 g) was dissolved in 40 ml of methanol. 33% Aqueous acetic acid (15 ml) was added followed by 0.20 g of 10%
Pd-C, then the reaction vessel was flushed with N2. The atmosphere inside the flask was replaced with HZ and the mixture was stirred rapidly under an atmosphere of H2 for 3 hours. The suspension was filtered through a 0.2 ~m frit and the clear solution was concentrated to dryness in vacuo. The residue was dissolved in approximately 20 ml of distilled water, frozen and lyophilized to obtain 1.47 g (95%) of the desired amine compound (Seq ID No. 1) as a white solid.

1 H NMR (400 MHz, CD30D): 8 7.02 (d, 2H), 6.69 (d, 2H), 5.09 (d, 1 H), 5.01 (d, 1 H), 2.77 (dd, 1 H), 1.15 (d, 3H).
FAB-MS (Li), m/z 1055 (MH + Li)+
s 1 o HOAc ~ H2 OH
O
HO N
.,,, H H
O N
O
15 H2N ' .,~~H
HO NH
O H H, N
N (5) I'~H O I'~OH Seq. ID No. 1 HO
A. Preparation of Intermediate Benzyloxycarbonyl Compound 2s ~Sec~ ID No. 1) The amine of formula (4) from Example 4 (200 mg, 0.1 RO
mmol) and pentafluorophenyl N-benzyloxycarbonyl-3-aminopropanoate were dissolved in 1 ml of dimethylformamide. Diisopropylethylamine (0.035 ml, 0.198 mmol) was added and the mixture was stirred at 3 o ambient temperature for 1 hour. The reaction mixture was diluted with 2 mls methanol and purified by preparative HPLC (C18 "DELTAPAK", step gradient: 70% A/30% B to 48% A/ 52% B, 48 ml fractions). The appropriate fractions as determined by UV absorbance (220, 277 nm) were combined, frozen and lyophilized to produce 100 mg (44%) of the desired intermediate.

O
N~NH

21 ~ s757 1 H NMR (400 MHz, CD30D): 8 7.32 (m, SH), 7.01 (d, 2H), 6.69 (d, 2H), 5.64 (bd, 1 H), 1.18 (d, 3H).
FAB-MS (Li), m/z 1259 (MLi)+
B. Preparation of 3-aminopropanoyl Compound of formula (5); Compound I-1 RII=H; RBI=CO(CH2)2NH2 (Seq ID
No. 1 Benzyloxycarbonyl compound from Part A (94 mg, 0.075 1 o mm°1) was dissolved in a mixture of 3 ml methanol, 1 ml of water and 0.2 ml of acetic acid. 10% Pd-C (48 mg) was added and the vessel was flushed with N2 gas. Next, the vessel was flushed with H2 and the mixture was stirred vigorously under 1 atm H2 for 2 hours. Removal of the volatiles in vacuo gave a solid. The solid was dissolved in about 4 ml of 50% aqueous acetonitrile, frozen and lyophilized to give 80 mg (91 %) of the desired compound of formula (5) as a white solid.
1 H NMR (400 MHz, CD30D): 8 7.01 (d, 2H), 6.69 (d, 2H), 6.67 (d, 1 H), 5.10 (d, 1 H), 4.99 (d, 1 H), 3.12 (m, 2H), 1.91 (s, 3H), 1.17 (d, 3H).
2o FAB-MS (Li), m/z 1125 (MLi)+

21 ~ s757 H3CHN OH ~~
s HO O O
N H
H N
~~~'H
p N O
O HN OH
H2N ' .,n H H...,.
to HO NH O \
O H H~, N
N (6) ~H O ~~~OH Seq. ID No. 1 OH
~s HO
Preparation of N-Methylamino Compound of formula (6); Compound I-~II=H; RIII=CH3) ~~Sec~ ID No. 1 ) The amine of formula (S) from Example 5 (45.6 mg, 0.135 mmol) was dissolved in 0.5 ml of dry dimethylformamide.
Iodomethane (0.021 ml, 0.338 mmol) was added followed by diisopropylethylamine (0.0824 ml, 0.473 mmol). After stirring at 2s ~ ambient temperature for 24 hours, the volatiles were removed in vacuo and the crude product was analyzed by mass spectrometry.
FAB-MS (Li), m/z 1068 (MLi)+

2'/18757 ~ 2HC1 H2N~ H
N OH
HO O
N
.,,. H H
O N
O
1o H2N ', .",H
HO NH
O H H, N
N
~'H O ~°~OH Seq. ID No. 1 OH
HO
A. Preparation of Intermediate Nitrile(N-Cyanomethyl) 2o Compound I-1; RII=H; RBI--CH~CN (Seq ID No. 1) The amine compound prepared as described in Example 4 (500 mg, 0.451 mmol) was dissolved in 3 ml of dry dimethylformamide. Bromoacetonitrile that had been prepurified by passing through a small plug of magnesium sulfate-sodium bicarbonate (0.063 ml, 0.902 mmol), was added followed by diisopropylethylamine (0.157 ml, 0.902 mmol). The clear reaction mixture was stirred for 12 hours and then diluted with a small volume of water. The solution was purified by preparative HPLC (C18 "DELTAPAK", step gradient: 70%
A/30% B to 47% A/53% B, 48 ml fractions). The appropriate 3o fractions, as determined by UV absorbance at 220 and 277 nm, were pooled, frozen and lyophilized to yield 338 mg (62%) of the desired intermediate cyanomethyl compound as a water insoluble solid.
1 H NMR (400 MHz, CD30D): b 7.01 (d, 2H), 6.69 (d, 2H), 5.12 (dd, 1 H), S.O1 (dd, 1 H), 3.80 (s, 2H), 2.76 (dd, 1 H), 1.15 (d, 3H).
FAB-MS (Li), m/z 1094 (MH+Li)+

B. Preparation of N-aminoethyl Compound of formula (7);
Compound I-I: RB=H: RIB=(CH~~,N-2H ~Se~ ID No. I~
The nitrite (cyanomethyl) compound prepared above (300 mg, 0.249 mmol) was dissolved in 5.0 ml of methanol. Next, nickel (II) chloride hexahydrate (237 mg, 0.997 mmol) was added. Sodium borohydride ( 189 mg, 4.99 mmol) was added to the solution in three portions. A black precipitate formed immediately and the mixture was stirred for 15 minutes at ambient temperature. The heterogeneous mixture was diluted with about 20-40 ml of water and approximately l0 10-15 ml of 2N HC1 was added. Stirring was continued for 45 minutes until the black precipitate had dissolved and a blue-green solution rernained. Purification was accomplished by preparative HPLC (C 1 R
"DELTAPAK", step gradient: 70% A/30% B to 55% A/45% B, 48 ml fractions). The appropriate fractions, as determined by UV absorbance i s at 220 and 277 nm, were pooled, frozen and lyophilized to yield 1 RO mg (55%) of the desired product. The material was dissolved in 30 ml of water and passed through an ion exchange column (CI- form), rinsing with distilled water. The solution was frozen and lyophilized to obtain 20 149 mg (94% recovery) of the desired aminoethyl compound of formula (7) Seq ID NO. I as a white solid.
I H NMR (400 MHz, CD30D): 8 7.01 (d, 2H), 6.69 (d, 2H), S. I 1 (dd, 1 H), 5.07 (dd, 1 H), I . I 4 (d, 3H).
FAB-MS (Li), m/z 109 (MH+Li)+

H2N ,OH
H~ O N
H
L,,~H
N
NC O
.,..H
l0 HO NH
H H N
N ,. C8) H O .~~OH Seq ID. No. 2 HO
A. Preparation of Intermediate Azide Compound (Seq ID
No. 477 2o pneumocandin BO nitrite (Seq ID No: 20) (2.00 g, 1.91 mmol) was dissolved in 24 ml of 2M LiC104 - diethyl ether.
Triethylsilane (2.00 ml) followed by trifluoroacetic acid (1.00 ml) was added and the mixture was rapidly stirred at ambient temperature for 6 hours. The mixture was poured into 300 ml of water, stirred for 15 minutes and filtered. The filter cake was dissolved in a minimal amount of methanol and the solvent removed in va uo. The residual water was azeotroped with 100% ethanol and the residue was subjected to high vacuum overnight to remove volatiles to obtain a product (Seq ID No.
17) mono-reduced at the benzylic carbon.
3 o The crude solid from above and sodium azide ( I .26 g, I 9.4 mmol) were placed in a roundbottom flask equipped with a stirring bar and cooling bath. Trifluoroacetic acid (50 ml) was slowly added, the cooling bath was removed and the mixture was stirred for 2 hours. It was poured into 300 ml of water and filtered. The solid was dissolved in methanol, rotovaped and pumped under high vacuum to remove volatiles. The crude material was purified by preparative HPLC (C18 "DELTAPAK", step gradient: 55 % A/45 % B to 45 % A/55 % B, 56 ml fractions). The appropriate fractions, as determined by W absorbance at 220 and 277 nm, were pooled, frozen and lyophilized to yield 0.59 g (29%) of the desired intermediate azide (Seq ID No. 47).
1 H NMR (400 MHz, CD30D): 8 7.00 (d, 2H), 6.69 (d, 2H), 5.34 (d, 1 H), 5.07 (d, 1 H), 5.00 (m, 1 H), 2.88 (dd, 1 H), 1.17 (d, 3H).
FAB-MS (Li), m/z 1036 (M-N2+Li)+
B. Preparation of Compound of Formula ~Rl (Seq ID No. 4R~
The purified azide from Part A (0.15 g, 0.142 mmol) was dissolved in a mixture of 4 ml methanol, 1 ml water and 0.5 ml of acetic acid. 10% Pd-C (SO mg) was added to the solution. The reaction i s flask was flushed with N2, then with H2. The mixture was rapidly stirred at ambient temperature for 5 hours under 1 atmosphere of H2.
Subsequent filtration through a 0.2 ~m frit and removal of the volatiles in vacuo produced 0.124 g (80%) of the desired compound of formula (8) Compound I-2; RII, RIB=H; RI=DMTD (Seq 1:D No. 2) as a white SOlld.
1 H NMR (400 MHz, CD30D): 8 7.00 (d, 2H), 6.69 (d, 2H), 5.04 (d, 1 H), 5.01 (m, 1 H), 2.79 (dd, 1 H), 1.18 (d, 3H).
FAB-MS (Li), m/z 1037 (MH+Li)+

- ~2CF~C02H H2N ,OH
HO ~ O
N H
.,,. H N

O HN ,OH
.,..H H..,.
to HO' NH O
H H, N
N Seq. ID No. 3 H O I~~OH
HO
Preparation of Amine Compound of Formula (9~ (Sed )D No. 3~.
The purified azide-nitrile from Example 8, Part A (44 mg , 0.0416 mmol) was dissolved in 1.5 ml of methanol followed by CoCl2~6H20 (59 mg, 0.25 mmol). Next, NaBH4 (8 X 12 mg, 2.50 mmol) was added cautiously in portions. The black, heterogeneous reaction mixture was stirred for 30 minutes at ambient temperature.
The reaction was quenched by adding about 1.5 ml of 2N HCl and 2s enough acetic acid to dissolve the precipitate. The pale solution was diluted with 3 ml of water and purified by preparative HPLC (C18 "ZORBAX", step gradient: 70% A/30% B to 60%A/40% B, 15 ml/min, 15 ml fractions). The appropriate fractions as determined by UV
absorbance at 210 and 277 nm, were pooled, frozen and lyophilized to obtain 38 mg (72%) of the desired compound of formula (9) as a white solid.
1 H NMR (400 MHz, CD30D): 8 6.99 (d, 2H), 6.70 (d, 2H), 5.11 (d, 1 H), 5.0 (m, 1 H), 3.05 (m, 2H), 1.17 (d, 3H).
FAB-MS (Li), m/z 1041 (MH+Li)+

211 ~~5a , H2N~ H
~3HC1 N OH
HO O
N
.,,. H H

O
.",H
HO' NH O ~~uJ
O H H; N
N Seq. ID No. 3 ,~~H .~~~OH
O
OH
HO
A. Preparation of Intermediate Bis-nitrite Compound (Compound I-2; RII=H; RIII=CH2CN; RI=DMTD) (Seq B7 No. 2l The nitrite-amine compound of Example 8 Part B (500 mg, 0.459 mmol) was dissolved in 3 ml of dry dimethylformamide.
Bromoacetonitrile that had been prepurified by passing through a small 2s ~ plug of magnesium sulfate-sodium bicarbonate (0.064 ml, 0.917 mmol), was added followed by diisopropylethylamine (0.155 ml, 0.917 mmol).
The reaction mixture was stirred at ambient temperature for 18 hours.
It was diluted with water and purified by preparative HPLC (C 18 "DELTAPAK", 60 ml/min, step gradient: 70% A/30% B to 50%
3 o A/50% B, 48 ml fractions). The appropriate fractions, as determined by UV absorbance at 220 and 277 nm, were pooled, frozen and lyophilized to obtain 198 mg (36%) of the desired Compound I-2;
RII=H; RIII=CH2CN
1 H NMR (400 MHz, CD30D): 8 7.00 (d, 2H), 6.69 (d, 2H), 5.08 (dd, 1 H), 5.01 (dd, 1 H), 3.73 (s, 2H), 2.79 (dd, 1 H), 1.18 (d, 3H).

FAB-MS (Li), m/z 1076 (MH+Li)+
B. Preparation of Compound of formula (101 (Seq ID No. 3) The bis-nitrile from Part A (184 mg, 0.155 mmol) was dissolved in 3 ml of methanol. NiCl2~6H20 ( 148 mg, 0.621 mmol) was dissolved in the methanol and NaBH4 (117 mg, 3.1 mmol) was added in three portions. After 5 minutes, CoCl2~6H20 (148 mg, 0.621 mmol) was added and stirred about 1 minute. An additional 117 mg of NaBH4 was added and stirring was continued for 15 minutes. Another 60 mg i o portion of NaBH4 was added to drive the reaction to completion. The mixture was diluted with water, acidified with 2N HCI and stirred until the black precipitate dissolved. Purification by preparative HPLC (C18 "ZORBAX", 15 ml/min, step gradient: 70% A/30% B to 55% A/45%
15 B, 22.5 ml fractions, 220, 277 nm) gave after lyophilization a solid.
The solid was dissolved in water and passed through an ion exchange column (Cl- form), frozen and lyophilized to give 81.1 mg (44%) of the desired compound of formula (10) (Compound I-3 (Seq ID No. 3) as a white solid.
1 H NMR (400 MHz, CD30D): b 7.00 (d, 2H), 6.70 (d, 2H), 3-3.3 (m, 6H), 1.18 (d, 3H).
FAB-MS (Li), m/z 1084 (MH+Li)+

In operations carried out in a manner similar to that described in Example 4, the appropriate cyclopeptide natural products or modified natural products obtained as described hereinafter on preparation of starting materials are in separate operations dissolved in LiC104-diethyl ether and to it is added with stirring trifluoroacetic acid and triethylsilane for 5 to 10 hours. The mixture is then poured into water, filtered, and the solid stirred with diethyl ether, then filtered and air dried to obtain cyclopeptide in which R 1 has been reduced to H.
The monoreduced compound is added to a preformed solution of HN3 (from NaN3 and trifluoroacetic acid) with cooling and 211 s~~~

stirred at room temperature form 30 minutes to one hour and then poured into water to obtain the azide product which is recovered in the manner previously described.
The azide is hydrogentated as previously described using Pd/C as catalyst and the product is recovered from the filtrate after separation of the catalyst.
The products obtained in this manner are as follows:
Example R I R2 R3 NRE RIn RI Seq.

No.

1 I H H CH2CONH2 H H C(H40C8H 17 12 12 H H CH2CN H H C(H40C8H 17 13 13 H H CH2CH~lI-12 H H C(H40C8H 17 14 i s 14 H CH3 CH3 H H C6H40C8H 17 1.5 In operations carried out in a manner similar to that 2o described in Example 7, the compounds of Examples 1 I, 13 and 14, are dissolved in dimethylformamide and added thereto are purified bromoacetonitrile followed by diisopropylethylamine and the mixture stirred from twelve to eighteen hours to produce a nitrite (an N-cyanomethyl) compound. The latter is purified by preparative HPLC.
2s The nitrite is dissolved in methanol and reduced chemically employing nickel (II) chloride and sodium borohydride to obtain animoethyl substituted compound as follows:

Example RI R2 R3 NRII RIII RI Seq ID

No.

15 H H CH2CONH2 H CH2CH2NH2 C I OH6OCgH 12 I ~

s 16 H H (CH2)2NH2 H CH2CHZNH2 CIOH60C8H17 14 17 H H CH3 H CH2CH2NH2 C I OH6OCgH 15 In operations carried out in a manner similar to that described in Example 1, 2 and 3, compounds having the substituents below may be prepared:
Example R R2 R3 NRII RIII RI S~

1 s ID

No.

20 OH OH CH2CH2NH2 H CH2CH2NI-i2 DMTD 14 2s ~ operations carried out in a manner similar to that described in Example I , the following compounds are prepared:
Example R R2 R3 NRB RIII RI Seq ID

No.

22 OH ~3 ~3 H CH2CH2NH2 C6H40CgH 10 I ~

23 OH CH3 H H CH2CH2NH2 C6H40CgH 11 1 ~

24 OH H CH2~2~2 H (CH2)3~2 DMTD 6 25 OH H CH2~2~2 N CH2CH2NH2 DMTD 6 2CF3COOH ~ CH \ CHs N ,OH
HO O /_ N
.,,~ H H

O
.,..H
l0 HO' NH O
O H H, N
N
HO,, '~~H .~'OH
O
OH (26) i5 Seq. ID No. 6 HO
The above compound is prepared in a manner similar to that described in Example 2, Part B, substituting dimethylamine for 2o ethylenediamine to obtain a compound of M.W. = 1334.43.

N OH
HO O ,- _ N
.,~ H H

to O
.,~~ H
HO NH
O H H,, N
N
HO,, '~~H ~~~OH
OH (27) Seq. ID No. 6 HO
The above compound is prepared in a manner similar to that in Example 26, substituting piperidine for dimethylamine to obtain a compound of M.W. 1374.

1000 compressed tablets each containing 500 mg of the compound of formula (2), [Compound I-6 (RII=H; RIII=2_aminoethyl) Seq ID No 6.], are prepared from the following formulation:
Compound Grams Compound of Example 2 500 Starch 750 Dibasic calcium phosphate, hydrous 5000 Calcium stearate . 2.5 21~s~~7 The finely powdered ingredients are mixed well and granulated with 10 percent starch paste. The granulation is dried and compressed into tablets.

1000 hard gelatin capsules, each containing 500 mg of the same compound are prepared from the following formulation:
1 o Compound r ms Compound of Example 2 500 Starch 250 Lactose 750 Talc 250 1 s Calcium stearate 10 A uniform mixture of the ingredients is prepared by blending and used to fill two-piece hard gelatin capsules.
2o EXAMPLE 30 An aerosol composition may be prepared having the following formulation:
25 .
Per Canister Compound of Example 2 24 mg Lecithin NF Liquid Concd. 1.2 mg Trichlorofluoromethane, NF 4.026 g Dichlorodifluoromethane, NF 12.15 g 250 milliliters of an injectible solution may be prepared by conventional procedures having the following formulation:
s Dextrose 12.5 g Water 250 ml Compound of Example 4 400 mg to The ingredients are blended and thereafter sterilized for use.
PREPARATION OF STARTING MATERIALS:
i s A-4 when RI is DMTD may be produced by cultivating Zalerion arboricola ATCC 206868 in nutrient medium with mannitol as the primary source of carbon as described in U.S. Patent No. 5,021, 341, June 4, 199 I .
A-7 when RI is DMTD may be produced by cultivating 2o Zalerion arboricola ATCC 20868 in nutrient medium as described in U.S. Patent No. 4,931,352, June 5, 1990.
A-10 when R1 is linoleyl may be produced by cultivating Asper ig 1~ nidulans NRRL 11440 in nutrient medium as described in U.S. Patent No. 4,288,549, September 8, 1981.
2 s A-11 when R1 is 1 I -methyltridecyl may be produced by cultivating Aspergillus s~dc~wi in nutrient medium as described in J.
Antibiotics XL (No. 3) p 28 (1987).
A-12 may be produced by cultivation of aleri n arboricola ATCC 20958 in nutrient medium as described in copending 3o application Serial No. 07/630,457, filed December 19, 1990 (Atty Docket No. 18268).
Compounds in which R 1 is H may be produced as described in Example 4, Part A.

21 ~ ~~5 a Compounds in which R3 is CH2CN such as A-2, A-5 and A-8 may be produced by the reaction of a compound having a carboxamide group in the corresponding position with excess cyanuric chloride in an aprotic solvent. Molecular sieves may be employed in this reaction. After completion of the reaction, the sieves, if employed, are removed, and the filtrate concentrated to obtain the nitrite compound as more fully described in copending application, Ser No.
936,434, September 3, 1992.
Compounds in which R3 is CH2CH2NH2 such as A-3, A-6 1 o and A-9 may be produced by either a chemical or catalytic reduction of the nitrite. It is conveniently carried out employing large molar excess of sodium borohydride with cobaltous chloride as more fully described in copending application Ser. No. 936,558, September 3, 1992.
Starting materials in which RI is a different group from that of the natural product may be obtained by deacylating the lipophilic group of the natural product by subjecting the natural product in a nutrient medium to a deacylating enzyme until substantial deacylation occurs, said enzyme having first been obtained by cultivating a microorganism of the family Pseudomondaceae or Actino~lanaceae, as 2o described in Experentia 34, 1670 (1978) or U.S. 4,293,482, recovering the deacylated cyclopeptide, and thereafter acylating the deacylated cyclopepetide by mixing together with an appropriate active ester RICOX to obtain Compound A with the desired acyl group.

SEQUENCE LISTING
(1) GENERAL INFORMATION
(i) APPLICANTS: BALKOVEC, JAMES M.
BLACK, REGINA M.
BOUFFARD, FRANCES AILEEN
(ii) TITLE OF INVENTION: AZA CYCLOPEPTIDE COMPOUNDS
(iii) NUMBER OF SEQUENCES: 60 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: ELLIOTT KORSEN
(B) STREET: P.O. BOX 2000, 126 EAST LINCOLN AVE.
(C) CITY: RAHWAY
(D) STATE: NEW JERSEY
(E) COUNTRY: USA
(F) ZIP: 07065 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: FLOPPY DISK
(B) COMPUTER: MACINTOSH CENTRIS 650 (C) OPERATING SYSTEM 7.1 (D) SOFTWARE: MICROSOFT WORD 5.1a (vi) CURRENT APPLICATION DATE:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA: NONE
(A) APPLICATION NUMBER:
(B) FILING DATE:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: ELLIOTT KORSEN
(B) REGISTRATION NUMBER: 32,705 (C) REFERENCE/DOCKET NUMBER: 18955 (ix) TELECOMMUNICATION INFORMATION
(A) TELEPHONE: 908-594-5493 (B) TELEFAX: 908-594-4720 (C) TELEX:
(2) INFORMATION FOR SEQ ID N0: 1 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

21~s~~~

(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 1 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 2 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 2 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 3 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 4 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:

(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID No: 5 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 6 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 7 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 7 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 8 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 8 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 9 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 10 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10 Xaa Ser Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 11 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 11 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 12 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 13 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

2118~~~

(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 13 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 14 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACTD
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 15 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 16 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16 Xaa Thr Xaa Xaa Xaa Xaa - 55 ' 18955 (2) INFORMATION FOR SEQ ID N0: 17 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 17 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 18 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 18 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 19 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 19 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 20 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 20 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 21 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 22 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 23 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 24 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 25 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 26 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 26 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 27 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 27 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 28 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

21~8~~~

(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 28 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 29 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 30 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 31 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 32 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

211 s7~~

(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 32 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 33 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 33 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 34 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCLTLAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 34 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 36 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:

211 s~~~
- 6~ ' 18955 (A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 36 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 37 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 37 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 38 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 39 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39 Xaa Thr Xaa Xaa Xaa Xaa 21~s~~~
- 61 ' 18955 (2) INFORMATION FOR SEQ ID N0: 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40 Xaa Ser Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 41 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 42 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 43 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 43 Xaa Thr Xaa Xaa Xaa Xaa _ 21 ~ s~~~

(2) INFORMATION FOR SEQ ID NO: 44 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 45 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 46 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 47 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE

' 63 ' 18955 (xi) SEQUENCE DESCRIPTION: SEQ ID N0: 47 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 48 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 48 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 49 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 50 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 51 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 51 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 52 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 53 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 54 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 55 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR

21's~57 (ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 56 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID NO: 57 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 57 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 58 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID N0: 58 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 59 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59 Xaa Thr Xaa Xaa Xaa Xaa (2) INFORMATION FOR SEQ ID N0: 60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 (B) TYPE: AMINO ACID
(C) STRANDEDNESS: NA
(D) TOPOLOGY: CIRCULAR
(ii) MOLECULE TYPE:
(A) DESCRIPTION: PEPTIDE
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60 Xaa Thr Xaa Xaa Xaa Xaa

Claims (52)

1. A compound having the formula (I) wherein:
R1 is H or OH;
R2 is H, CH3 or OH;.
R3 is H, CH3, CH2CN, CH2CH2NH2 or CH2CONH2;
RI is C9-C21 alkyl, C9-C21 alkenyl, C1-C10 alkoxyphenyl or C1-C10 alkoxynaphthyl;
RII is H, C1-C4 alkyl, C3-C4 alkenyl, (CH2) 2-4OH, (CH2) 2-4 NRIV RV, CO (CH2) 1-4NH2;
RIII is H, C1-C4 alkyl, C3-C4 alkenyl, (CH2) 2-4OH, (CH2) 2-4 NRIV RV, or R II and R III taken together are -(CH2)4-, -(CH2)5-, -CH2)2O(CH2)2- or -(CH2)2-NH-(CH2)2;
R IV is H or C1-C4 alkyl, R V is H or C1-C4 alkyl; or an acid addition salt thereof.

2. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is OH, R2 is H, R3 is CH2CONH2, R I is 9,11-dimethyltridecyl, R II is H and R III is -CH2CH2NH2.

3. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is OH, R2 is H, R3 is CH2CH2NH2, R I is 9,11-dimethyltridecyl, R II is H and R III is -CH2CH2NH2.

4. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is OH, R2 is H, R3 is CH2CONH2, R I is 9,11-dimethyltridecyl, and R II and R III are H.

5. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is H, R2 is H, R3 is CH2CONH2, R I is 9,11-dimethyltridecyl, and R II and R III are H.

6. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is H, R2 is H, R3 is CH2CONH2, R I is 9,11-dimethyltridecyl, R III is H and R II is COCH2CH2NH2.

7. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is H, R2 is H, R3 is CH2CONH2, R I is 9,11-dimethyltridecyl, R II
is H, R III 1S -CH2CH2NH2.

8. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is H, R2 is H, R3 is CH2CH2NH2, R I is 9,11-dimethyltridecyl, R II and R III are H.

9. A compound of formula (I), or an acid addition salt thereof, according to claim 1, wherein R1 is H, R2 is H, R3 is CH2CH2NH2, R I is 9,11-dimethyltridecyl, R II is H and R III is CH2CH2NH2.

10. A pharmaceutically acceptable acid addition salt of a compound as defined in any one of claims 1 to 9.

11. A pharmaceutically acceptable acid addition salt of a compound as defined in claim 2.

12. A pharmaceutically acceptable acid addition salt of a compound as defined in any one of claims 1 to 9, with an acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, sulfuric, maleic, citric, acetic, tartaric, succinic, oxalic, malic and glutamic acids.

13. A pharmaceutically acceptable acid addition salt of a compound as defined in claim 2, with an acid selected from the group consisting of hydrochloric, hydrobromic, phosphoric, sulfuric, maleic, citric, acetic, tartaric, succinic, oxalic, malic and glutamic acids.

14. An antimicrobial composition comprising a compound of formula (I), as defined in any one of claims 1 to 9, or a pharmaceutically acceptable acid addition salt thereof, in admixture with a pharmaceutically acceptable carrier.

15. An antimicrobial composition comprising the compound of formula (I), as defined in Claim 2, or a pharmaceutically acceptable acid addition salt thereof, in admixture with a pharmaceutically acceptable carrier.

16. An antimicrobial composition comprising a pharmaceutically acceptable acid addition salt of claim or 12, in association with a pharmaceutically acceptable carrier.

17. An antimicrobial composition comprising a pharmaceutically acceptable acid addition salt of claim 11 or 13, in association with a pharmaceutically acceptable carrier.

18. A compound of formula (I), or an acid addition salt thereof, as defined in any one of claims 1 to 9, for use in controlling mycotic infections.

19. A compound of formula (I), or an acid addition salt thereof, as defined in any one of claims 1 to 9, for use in controlling pneumocystis pneumonia in immune-compromised patients.

20. A compound of formula (I), or an acid addition salt thereof, as defined in claim 2, for use in controlling mycotic infections.

21. A pharmaceutically acceptable salt of claim 10 or 12, for use in controlling mycotic infections.

22. A pharmaceutically acceptable salt of claim 11 or 13, for use in controlling mycotic infections.

23. A compound of formula (I), or an acid addition salt as defined in claim 2, for use in controlling pneumocystis pneumonia in an immune-compromised patient.

24. A pharmaceutically acceptable salt of claims 10 or 12, for use in controlling pneumocystis pneumonia in an immune-comprised patient.

25. A pharmaceutically acceptable salt of claim 11 or 13, for use in controlling pneumocystis pneumonia in an immune-compromised patient.

26. Use of a compound of formula (I), as defined in any one of claims 1 to 9, or an acid addition salt thereof, in the manufacture of a medicament for controlling mycotic infections.

27. Use of a compound of formula (I), as defined in claim 2, or an acid addition salt thereof, in the manufacture of a medicament for controlling mycotic infections.

28. Use of a pharmaceutically acceptable salt of claims 10 or 12, in the manufacture of a medicament for controlling mycotic infections.

29. Use of a pharmaceutically acceptable salt of claim 11 or 13, in the manufacture of a medicament for controlling mycotic infections.

30. Use of a compound of formula (I), as defined in any one of claims 1 to 9, or an acid addition salt thereof, in the manufacture of a medicament for controlling pneumocystis pneumonia in an immune-compromised patient.

31. Use of a compound of formula (I), as defined in claim 2, or an acid addition salt thereof, in the manufacture of a medicament for controlling pneumocystis pneumonia in an immune-compromised patient.

32. A pharmaceutically acceptable salt of claim 10 or 12, for use in the manufacture of a medicament for controlling pneumocystis pneumonia in an immune-compromised patient.

33. A pharmaceutically acceptable salt of claim 11 or 13, for use in the manufacture of a medicament for controlling pneumocystis pneumonia in an immune-compromised patient.

34. A compound having the formula:

or a pharmaceutically acceptable acid addition salt thereof with an inorganic or organic acid.

35. A compound having the formula:

or a pharmaceutically acceptable acid addition salt thereof with an inorganic or organic acid.

36. A pharmaceutically acceptable acid addition salt of a compound of claim 34 or 35, wherein said acid is an inorganic acid.

37. A pharmaceutically acceptable acid addition salt of a compound of claim 34 or 35, wherein said acid is an organic acid.

38. A salt of claim 37, wherein said acid is maleic acid.

39. A salt of claim 37, wherein said acid is citric acid.

40. A salt of claim 37, wherein said acid is acetic acid.

41. A salt of claim 37, wherein said acid is tartaric acid.

42. A salt of claim 37, wherein said acid is succinic acid.

43. A salt of claim 37, wherein said acid is oxalic acid.

44. A salt of claim 37, wherein said acid is malic acid.

45. A salt of claim 37, wherein said acid is glutamic acid.

4.6. A salt of claim 36, wherein said acid is hydrochloric acid.

47. An antimicrobial pharmaceutical com-position comprising an acceptable, antimicrobially effective amount of a compound of formula (I) as defined in claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

48. An antimicrobial pharmaceutical composition comprising an acceptable, antimicrobially effective amount of a compound or salt of any one of claims 34 to 46, in association with a pharmaceutically acceptable carrier.

49. A compound of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, or a pharmaceutically acceptable salt thereof for use in the control of filamentous fungi and yeasts, treatment of mycotic infections, or control of pneumocystis pneumonia in an immune-compromised patient.

50. A compound or salt of any one of claims 34 to 46, for use in the control of filamentous fungi and yeasts, treatment of mycotic infections, or control of pneumocystis pneumonia in an immune-compromised patient.

51. Use of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the control of filamentous fungi and yeasts, treatment of mycotic infections, or control of pneumocystis pneumonia in an immune-compromised patient.

52. Use of a compound or salt of any one of claims 34 to 46, in the manufacture of a medicament for the control of filamentous fungi and yeasts, treatment of mycotic infections, or control of pneumocystis pneumonia in an immune-compromised patient.